nortriptyline 10mg tablets
king pharmaceuticals ltd - nortriptyline hydrochloride - oral tablet - 10mg
nortriptyline 25mg tablets
king pharmaceuticals ltd - nortriptyline hydrochloride - oral tablet - 25mg
cilostazol 100mg tablets
a a h pharmaceuticals ltd - cilostazol - oral tablet - 100mg
stirlescent 250mg effervescent tablets
stirling anglian pharmaceuticals ltd - naproxen - effervescent tablet - 250mg
ethambutol 100mg tablets
esteve pharmaceuticals ltd - ethambutol hydrochloride - oral tablet - 100mg
ethambutol 400mg tablets
esteve pharmaceuticals ltd - ethambutol hydrochloride - oral tablet - 400mg
diclofenac sodium gel
padagis israel pharmaceuticals ltd - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium topical gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. diclofenac sodium topical gel is contraindicated in the following patients: risk summary use of nsaids, including diclofenac sodium topical gel, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including diclofenac sodium topical gel, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of diclofenac sodium topical gel in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2-4% f
opsumit
j-c health care ltd - macitentan - film coated tablets - macitentan 10 mg - macitentan - opsumit ® is an endothelin receptor antagonist (era) indicated for the treatment of pulmonary arterial hypertension (pah, who group i) to delay disease progression. disease progression included: death, initiation of intravenous (iv) or subcutaneous prostanoids or clinical worsening of pah (decreased 6-minute walk distance, worsened pah symptoms and need for additional pah treatment). opsumit also reduced hospitalization for pah.
sevorane
abbvie biopharmaceuticals ltd, israel - sevoflurane - liquid for inhalation - sevoflurane 100 % - sevoflurane - sevoflurane is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
pentasa slow release granules 4 g.
ferring pharmaceuticals ltd - mesalazine - granules - mesalazine 4000 mg - mesalazine - mild to moderate ulcerative colitis or crohn's disease.